Stockscreener 앱 받기
35.42
1.09%
-0.39
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 3.9%Time to Sell? - MarketBeat
Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times
Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Zacks Research Issues Negative Forecast for AGIO Earnings - MarketBeat
Fmr LLC Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director David Scadden sells $9,256 in stock By Investing.com - Investing.com Australia
Agios Pharmaceuticals director David Scadden sells $9,256 in stock - Investing.com
Agios Pharmaceuticals Enters Oversold Territory (AGIO) - Nasdaq
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com
Agios Pharmaceuticals Shares Cross Below 200 DMA - Nasdaq
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Analyst Ratings For Agios Pharmaceuticals - Benzinga
Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank - Yahoo Finance
Frazier Life Sciences Management L.P. Acquires 172,180 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug - Yahoo! Voices
Alpha Thalassemia Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Agios Pharma, Novo Nordisk, Bristol-Myers Squibb, Genmedicn Biopharma - Barchart
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug - Yahoo! Voices
ASH 2024: Agios’ mitapivat checks off efficacy; liver toxicity a concern - BioWorld Online
Agios reports results from late-stage study of its thalassemia treatment (NASDAQ:AGIO) - Seeking Alpha
Oncology Market Overview and Leading Players: Daiichi Sankyo - openPR
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - br.ADVFN.com
Agios Phase 3 Trial Breakthrough: Mitapivat Shows 3x Better Results for Thalassemia Treatment - StockTitan
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? - MSN
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios - Yahoo Finance
Parkman Healthcare Partners LLC Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals: A Long Overdue Follow Up (NASDAQ:AGIO) - Seeking Alpha
(AGIO) Trading Advice - Stock Traders Daily
Erste Asset Management GmbH Acquires Shares of 2,184,900 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Caligan Partners LP Has $25.76 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Bellevue Group AG - MarketBeat
PDT Partners LLC Sells 18,545 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Vestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Summit Partners Public Asset Management LLC Acquires Shares of 101,730 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Intech Investment Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Fisher Asset Management LLC Grows Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Loomis Sayles & Co. L P - MarketBeat
AGIO (Agios Pharmaceuticals) 3-Year EPS without NRI Growth Rate : -9.90% (As of Sep. 2024) - GuruFocus.com
Beta-thalassemia Market is Predicted to Exhibit Remarkable Growth During the Forecast Period, asserts DelveInsight | Phoenicia, EdiGene, Imara, Agios, Ionis - Barchart
Alpha Thalassemia Pipeline Insights 2024: Therapies, Clinical - openPR
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update - Defense World
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):